The federal government's partial rescheduling of marijuana took effect April 22, 2026 - and now the Drug Enforcement Administration has announced it will move immediately to the next question: whether marijuana as a whole, not just FDA-approved drug products and state-licensed medical cannabis, belongs in Schedule III of the Controlled Substances Act. An expedited administrative hearing begins June 29, 2026. For state-licensed cannabis operators across both medical and adult-use markets, that date carries more weight than almost anything else on the regulatory calendar this year.
What the April Order Actually Did - and What It Left Untouched
The April 22 final order, issued by the acting U.S. attorney general and the DEA under treaty-implementation authority, moved two specific categories of marijuana from Schedule I to Schedule III. The first: FDA-approved drug products containing naturally derived delta-9 THC from Cannabis sativa L. The second: marijuana and marijuana products operated under a state-issued medical marijuana license - meaning a license authorizing manufacture, distribution, or dispensing for medical purposes.
Here's the catch. Recreational cannabis - the adult-use market that now dominates state-licensed revenue in a growing number of states - stays in Schedule I. So does synthetically derived THC. Hemp, as defined under federal agricultural law, is unaffected. Any marijuana product that doesn't fit neatly into the FDA-approved or state-medical-licensed categories remains where it has always been: the most restrictive tier of federal drug control.
To put it plainly, the April order was a significant step forward for medical cannabis operators and pharmaceutical interests. It was not a broad federal liberalization. Dispensaries selling adult-use products are operating in the same federal legal limbo they occupied before April 22.
The June Hearing Changes the Calculus for Adult-Use Operators
The June 29, 2026, administrative hearing is where that changes - or doesn't. The DEA's expedited process will consider reclassifying marijuana as a whole to Schedule III, regardless of whether a product carries FDA approval or a state medical license. That would pull recreational cannabis out of Schedule I for the first time in the CSA's history.
The business implications of a broad Schedule III reclassification are substantial. The most immediate and financially material one is Section 280E of the Internal Revenue Code. Under current law, 280E bars businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses - payroll, rent, marketing, POS software, compliance infrastructure - from federal taxable income. For adult-use dispensaries, which carry the same operational costs as any specialty retailer, 280E has functioned as a structural tax penalty with no equivalent in any other legal retail sector. The April order already removed 280E's bite for state-licensed medical operators. A successful broad rescheduling would extend that relief to adult-use licensees.
The acting attorney general also encouraged the Treasury Department to consider retrospective 280E relief for medical licensees who operated under state licenses in prior tax years - though the order explicitly stops short of making any determination about actual tax liability. Operators and multi-state companies should treat that as a signal worth watching, not a guarantee worth banking on, and should have tax counsel engaged now.
The Expedited Registration Pathway - And Why Medical Operators Should Move Quickly
For state-licensed medical cannabis businesses, the April order does something concrete right now. It creates an expedited DEA registration pathway that allows applicants to submit existing state credentials as conclusive evidence of state-law authorization. Manufacturers, distributors, and dispensaries holding valid state medical marijuana licenses can apply for DEA registration as Schedule III handlers without going through the typical federal application process from scratch.
The DEA has set a 60-day priority window from the order's publication date. Applicants who file within that window may continue operating under their state licenses while their DEA application is pending, and the agency has committed to a six-month processing target for those priority submissions. That's not a trivial window. Missing it means waiting in a standard queue with no operational continuity protection.
A few operational realities to understand about this registration:
- DEA registration automatically suspends if the underlying state license is suspended, revoked, or expires - meaning state compliance is now directly tied to federal standing.
- State-required records, labeling, and packaging standards are accepted in lieu of most federal requirements, with one addition: the statutory warning label required under 21 U.S.C. § 825(c) must appear on product packaging.
- State medical marijuana certifications - the equivalent of a practitioner's authorization for a patient - are sufficient to permit dispensing, provided they include the patient's name and address, are dated and signed on the day of issuance, and identify the issuing practitioner.
Seed-to-sale tracking, METRC integrations, and existing compliance logs built around state requirements will largely satisfy federal record-keeping obligations under the order. That's a deliberate design choice - the DEA explicitly stated it will accept state records to the maximum extent permissible under federal law and treaty obligations. For compliance teams that have spent years building state-aligned infrastructure, this is meaningful. It does not, however, eliminate the need to verify that existing documentation practices actually meet the baseline federal standards now layered on top.
Legal Risk and What Stakeholders Should Monitor
The DEA's legal basis for the April order is worth understanding, because it may face challenge. The agency acted under 21 U.S.C. § 811(d)(1), which permits the attorney general to schedule substances based on U.S. treaty obligations under the Single Convention on Narcotic Drugs - without the notice-and-comment rulemaking that normally governs CSA scheduling changes. The DEA took the position that the Administrative Procedure Act's standard procedural requirements don't apply here. That is a contestable legal theory. If it draws litigation - and it very well might - the stability of the April order and the June hearing process could both be affected.
That said, the June 29 hearing itself proceeds through the CSA's standard administrative hearing process, which carries its own procedural protections. Stakeholders who want to participate - whether as operators, trade associations, researchers, or patient advocates - should monitor DEA announcements for participation procedures closely. Administrative hearings of this type accept written comments and often formal testimony from interested parties, and the record built in that proceeding will shape the outcome.
Beyond the DEA, watch for guidance from the IRS on 280E treatment going forward, from the FDA on how Schedule III status affects cannabis product approval pathways, and from HHS on any downstream healthcare or insurance implications for medical cannabis access. None of those agencies have issued detailed guidance as of the April order's effective date, and the gaps are real.
The June 29 hearing is the most consequential near-term event in federal cannabis regulation - full stop. Its outcome will determine whether the adult-use market gets the federal footing it has never had, or whether recreational cannabis operators continue building businesses under a Schedule I designation that contradicts state law in a growing majority of U.S. jurisdictions. Operators, investors, and legal counsel across the industry have roughly two months to prepare their positions. That's not much time.
